FPR2 and central nervous system disorder: To date, several studies in different animal models of neuroinflammation have shown that administration of LXA4, an endogenous agonist of FPR2, could be useful to inhibit microglial activation and attenuation of neuroinflammation, thus opening the door to new therapeutic strategies for the treatment of CNS disorders.